Skip header and navigation

Refine By

2902 records – page 1 of 291.

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

[2 vaccine dosages for basic prevention of whooping cough in children over 2 years of age?]

https://arctichealth.org/en/permalink/ahliterature34713
Source
Lakartidningen. 1996 Jul 10;93(28-29):2564
Publication Type
Article
Date
Jul-10-1996
Author
L. Gothefors
J. Storsaeter
Source
Lakartidningen. 1996 Jul 10;93(28-29):2564
Date
Jul-10-1996
Language
Swedish
Publication Type
Article
Keywords
Age Factors
Child, Preschool
Denmark
Humans
Immunization Schedule
Pertussis Vaccine - administration & dosage
PubMed ID
8801406 View in PubMed
Less detail

[3',5'-cAMP phosphodiesterase inhibitors in the combined treatment of patients with rheumatoid arthritis]

https://arctichealth.org/en/permalink/ahliterature14188
Source
Lik Sprava. 1998 Aug;(6):34-7
Publication Type
Article
Date
Aug-1998
Author
O I Bakaliuk
M I Shved
M V Hrebenyk
Source
Lik Sprava. 1998 Aug;(6):34-7
Date
Aug-1998
Language
Ukrainian
Publication Type
Article
Keywords
3',5'-Cyclic-Nucleotide Phosphodiesterase - antagonists & inhibitors
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy - immunology - metabolism
Combined Modality Therapy
Comparative Study
Drug Evaluation
English Abstract
Glucosephosphate Dehydrogenase - blood - drug effects
Humans
Immunity, Cellular - drug effects
Immunity, Natural - drug effects
Lipid Peroxidation - drug effects
Papaverine - therapeutic use
Phosphodiesterase Inhibitors - therapeutic use
Prospidium - therapeutic use
Abstract
A study was made of clinical effectiveness and mechanism of action of the inhibitor of the specific 3',5'-cAMP phosphodiesterase papaverine in a therapeutic complex of measures designed to treat RA patients involving an immunodepressive preparation free from any cytopenic effect prospidin as a basic mediator. It has been shown that the papaverine antiarthritic action is associated with its positive effects on the unspecific component of the immune-complex inflammation, viz. processes of lipid peroxidation, activity of the antioxidant system of defence as well as on the vascular tone and microcirculation. All this improves tissue metabolism, and in this way enhances efficiency of RA basic therapy.
PubMed ID
9844866 View in PubMed
Less detail

6th Canadian Immunization Conference. Montreal, Quebec, 5 to 8 December, 2004. Oral scientific abstracts.

https://arctichealth.org/en/permalink/ahliterature173326
Source
Can Commun Dis Rep. 2005 Aug 1;31(15):161-7
Publication Type
Conference/Meeting Material
Article
Date
Aug-1-2005
Source
Can Commun Dis Rep. 2005 Aug 1;31(15):161-7
Date
Aug-1-2005
Language
English
French
Publication Type
Conference/Meeting Material
Article
Keywords
Canada
Humans
Immunization
Vaccines - therapeutic use
PubMed ID
16100790 View in PubMed
Less detail

1991-1996: Alaska's progress towards the goals of Healthy People 2000

https://arctichealth.org/en/permalink/ahliterature88238
Source
Alaska's Behavioral Risk Factor Surveillance System 6(1)
Publication Type
Report
Date
Feb-1998
Author Affiliation
State of Alaska Department of Health and Social Services
Source
Alaska's Behavioral Risk Factor Surveillance System 6(1)
Date
Feb-1998
Language
English
Geographic Location
U.S.
Publication Type
Report
Physical Holding
University of Alaska Anchorage
Keywords
Behavioral risk factors
Cholesterol screening
Cigarette smoking
Diabetes
Fruit and vegetable consumption
Heart disease
Inflluenza amd pneumonia immunizations
Mammography and clinical breast exams
Overweight
Pap tests
Physical activity
Proctoscopic exams
Safety belt use
Abstract
The Alaska Department of Health and Social Services implemented the Behavioral Risk Factor Surveillance System (BRFSS) in 1990 incooperation with the federal Centers for Disease Control and Prevention. The system gathers information about the health-related lifestyle choices of Alaskan adults related to leading causes of death such as heart disease, cancer and injury. The program is part of an ongoing national data collection system. Results are analyzed each year to improve our understanding of Alaskanhealth habits and to measure progress toward national and state health objectives. This report summarizes survey findings from1991 to 1996 and compares the results to selected national health objectives presented in the Healthy People 2000 publication.
Less detail

1995 behavioral risk factor survey highlights

https://arctichealth.org/en/permalink/ahliterature88230
Source
Alaska's Behavioral Risk Factor Surveillance System 5(1)
Publication Type
Report
Date
April-1997
Author Affiliation
State of Alaska Department of Health and Social Services
Source
Alaska's Behavioral Risk Factor Surveillance System 5(1)
Date
April-1997
Language
English
Geographic Location
U.S.
Publication Type
Report
Physical Holding
University of Alaska Anchorage
Keywords
Adult immunizations
Alcohol use
Behavioral risk factors
Breast cancer screening
Cervical cancer screening
Cholesterol screening
Chronic Disease
Colorectal cancer screening
Diabetes
Health care coverage
HIV/AIDS
Hypertension
Overweight
Premature death
Safety belt use
Tobacco use
Abstract
Behavior and lifestyle play an important part in determining ourhealth status and lifespan. Every day Alaskans make lifestyle choices that profoundly affect their health. Although heredity and environment play a part, the leading causes of death in Alaska (heart disease, cancer and unintentional injuries) are closely related to lifestyle factors. Lifestyle and behavioral factors that affect health include such things as diet, exercise, use of alcohol andtobacco, and preventive health practices. Many premature deathsand disabilities could be prevented through better control of thesebehavioral risk factors.
Less detail

[Ability of blood protein, typical of normal growth, to activate glycolysis and inhibit the Pasteur reaction]

https://arctichealth.org/en/permalink/ahliterature66133
Source
Ukr Biokhim Zh. 1977 Mar-Apr;49(2):78-82
Publication Type
Article
Author
V N Bila
V P Korotkoruchko
Source
Ukr Biokhim Zh. 1977 Mar-Apr;49(2):78-82
Language
Ukrainian
Publication Type
Article
Keywords
Anaerobiosis
Animals
Animals, Newborn - blood
Beta-Globulins - pharmacology
Blood Proteins - pharmacology
English Abstract
Female
Fetal Blood
Glycolysis - drug effects
Immune Sera - pharmacology
Muscles - metabolism
Oxygen
Pregnancy
Rabbits
Abstract
Formation of lactic acid by the extracts from the healthy rabbit muscles was studied as affected by the sera of embryos, newborn rabbits and pregnant female rabbits. The blood sera and beta-globulin isolated from them are established to activate anaerobic glycolysis and inhibit the Pasteur reaction. It is shown that protein typical of normal growth, belonging to beta-globulins and circulating in blood of the embryos, newborn rabbits from the first to the fifteenth day of development is "responsible" for this phenomena. Correlation is found between the precipitation test for detecting this protein and its biological effect on glycolysis and the Pasteur reaction.
PubMed ID
68614 View in PubMed
Less detail

Aboriginal immunity: Potential contribution to the outcome of hepatic infection and disease

https://arctichealth.org/en/permalink/ahliterature256661
Source
Page 89 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Publication Type
Conference/Meeting Material
Date
2010
ABORIGINAL IMMUNITY, POTENTIAL CONTRIBUTION TO THE OUTCOME OF HEPATIC INFECTION AND DISEASE J. Rempel University of Manitoba One of the main tasks of the immune system is to defend the body against infectious disease. Our laboratory has been evaluating First Nation (primarily Ojibwa/Cree
  1 document  
Author
Rempel J
Author Affiliation
University of Manitoba
Source
Page 89 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Date
2010
Language
English
Geographic Location
Canada
Publication Type
Conference/Meeting Material
Digital File Format
Text - PDF
Physical Holding
University of Alaska Anchorage
Keywords
Aboriginal people
Canada
Hepatitis C
Virus
Immune
Genetic tendency
First Nation
Notes
Part of Abstracts: Oral presentations. Chapter 2. Infectious Diseases and Sexual Health.
Documents
Less detail

2902 records – page 1 of 291.